首页> 外文期刊>BMC Systems Biology >Identification of putative drug targets for human sperm-egg interaction defect using protein network approach
【24h】

Identification of putative drug targets for human sperm-egg interaction defect using protein network approach

机译:使用蛋白质网络方法确定人精卵相互作用缺陷的假定药物靶标

获取原文
获取外文期刊封面目录资料

摘要

Background Sperm-egg interaction defect is a significant cause of in-vitro fertilization failure for infertile cases. Numerous molecular interactions in the form of protein-protein interactions mediate the sperm-egg membrane interaction process. Recent studies have demonstrated that in addition to experimental techniques, computational methods, namely protein interaction network approach, can address protein-protein interactions between human sperm and egg. Up to now, no drugs have been detected to treat sperm-egg interaction disorder, and the initial step in drug discovery research is finding out essential proteins or drug targets for a biological process. The main purpose of this study is to identify putative drug targets for human sperm-egg interaction deficiency and consider if the detected essential proteins are targets for any known drugs using protein-protein interaction network and ingenuity pathway analysis. Results We have created human sperm-egg protein interaction networks with high confidence, including 106 nodes and 415 interactions. Through topological analysis of the network with calculation of some metrics, such as connectivity and betweenness centrality, we have identified 13 essential proteins as putative drug targets. The potential drug targets are from integrins, fibronectins, epidermal growth factor receptors, collagens and tetraspanins protein families. We evaluated these targets by ingenuity pathway analysis, and the known drugs for the targets have been detected, and the possible effective role of the drugs on sperm-egg interaction defect has been considered. These results showed that the drugs ocriplasmin (Jetrea?), gefitinib (Iressa?), erlotinib hydrochloride (Tarceva?), clingitide, cetuximab (Erbitux?) and panitumumab (Vectibix?) are possible candidates for efficacy testing for the treatment of sperm-egg interaction deficiency. Further experimental validation can be carried out to confirm these results. Conclusion We have identified the first potential list of drug targets for human sperm-egg interaction defect using the protein interaction network approach. The essential proteins or potential drug targets were found using topological analysis of the protein network. These putative targets are promising for further experimental validation. These study results, if validated, may develop drug discovery techniques for sperm-egg interaction defect and also improve assisted reproductive technologies to avoid in-vitro fertilization failure.
机译:背景精子与卵的相互作用缺陷是导致不育病例体外受精失败的重要原因。蛋白质-蛋白质相互作用形式的许多分子相互作用介导了精卵膜相互作用过程。最近的研究表明,除实验技术外,计算方法(即蛋白质相互作用网络方法)还可以解决人精子与卵之间的蛋白质-蛋白质相互作用。到目前为止,还没有发现可治疗精卵相互作用的药物,药物发现研究的第一步是寻找生物过程中必需的蛋白质或药物靶标。这项研究的主要目的是通过蛋白质-蛋白质相互作用网络和独创性途径分析,确定假定的针对人类精卵相互作用缺乏的药物靶标,并考虑检测到的必需蛋白质是否是任何已知药物的靶标。结果我们建立了具有高可信度的人类精卵蛋白相互作用网络,包括106个节点和415个相互作用。通过对网络进行拓扑分析并计算一些指标(例如连通性和中间性),我们确定了13种必需蛋白作为推定的药物靶标。潜在的药物靶标来自整合素,纤连蛋白,表皮生长因子受体,胶原蛋白和四跨膜蛋白家族。我们通过创造力途径分析评估了这些靶标,并检测了已知的用于靶标的药物,并考虑了该药物对精卵相互作用缺陷的可能作用。这些结果表明,药物ocriplasmin(Jetrea?),吉非替尼(Iressa?),盐酸厄洛替尼(Tarceva?),克林替肽,西妥昔单抗(Erbitux?)和帕尼单抗(Vectibix?)可能是治疗精子-雄激素的候选药物。鸡蛋相互作用缺乏。可以进行进一步的实验验证以证实这些结果。结论我们已经使用蛋白质相互作用网络方法确定了人类精卵相互作用缺陷的第一个潜在药物靶标。使用蛋白质网络的拓扑分析发现了必需蛋白质或潜在的药物靶标。这些推定的目标有望用于进一步的实验验证。这些研究结果如果得到验证,可能会开发出针对精卵相互作用缺陷的药物发现技术,并且还将改善辅助生殖技术,从而避免体外受精失败。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号